Balance of anti-CD123 Chimeric Antigen Receptor (CAR) binding affinity and density for the targeting of Acute Myeloid Leukemia

      Chimeric Antigen Receptors (CARs)-redirected T lymphocytes are a promising immunotherapeutic approach, nowadays object of accurate preclinical evaluation also for Acute Myeloid Leukemia (AML) targeting. We recently developed a CAR against the CD123 antigen, found to be over-expressed on AML blasts and leukemic stem cells (LSCs). However, the potential recognition of low CD123-positive healthy tissues, through the so called “on-target-off-organ” effect, limits the safe clinical employment of CAR-T cells.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cytotherapy
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect